Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience Enters Strategic Partnership with SNBL

Published: Friday, April 25, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Agreement’s initial focus is for SNBL to promote Crown services to its Japanese client base.

Crown Bioscience, Inc. has announced that it has entered into a strategic partnership with Shin Nippon Biomedical Laboratories, Ltd., a Japan-based company engaged in the provision of preclinical and clinical drug development services for pharmaceutical companies.

The initial focus of the agreement is for Shin Nippon Biomedical Laboratories (SNBL) to promote Crown Bioscience (Crown) services to its Japanese client base, in doing so extending SNBL’s service offering.

As part of the agreement, SNBL shall be the exclusive representative for Crown in promoting Crown’s unique translational science services including the world’s largest collection of Patient Derived Xenograft (PDX) models.

The partnership is strategically important for Crown and marks another significant step in expanding its international footprint following the company’s recent expansion into Europe during which Crown acquired PRECOS Ltd in July 2013. SNBL has multiple facilities across Japan, the United States, China, and Cambodia and as such offers Crown access to a global target audience.

While Crown is the world’s leading supplier of oncology services, with a global footprint spanning three major continents in North America, Europe and Asia Pacific, Japan is seen as a market with significant further potential. As a result of the partnership, both companies will also look at the potential to co-develop new models and services leveraging their respective expertise in Oncology/Diabetes and non-human primate model development.

Jean-Pierre Wery, President of Crown comments, “This strategic partnership offers Crown an excellent opportunity to develop a greater understanding of the Japanese market in order to further develop unique cutting-edge models. It is the first time that SNBL has agreed to represent an overseas company in such a deal. We are delighted to be partnering with the largest preclinical contract research organization in Japan as part of our international business strategy to develop our services in the Far East.”

Ryoichi Nagata, CEO and President of SNBL comments, “SNBL is committed to providing our customers with fast and precise results across the entire drug development spectrum, from early discovery research to late-stage clinical trials. This unique partnership with Crown will enable us to strengthen our service offering, and also to collaborate on a variety of pre-clinical projects, utilizing unique clinically relevant models, with a shared goal of improving patient care and treatment outcomes. Our expertise in preclinical development provides a perfect complement to Crown’s existing global services.”

Jean-Pierre Wery continues, “We are looking forward to working with SNBL to increase business opportunities with prospective customers across Japan and the Far East. Japan is one of the fastest growing pharmaceutical markets and there is great potential to help our clients working in the pharmaceutical and biotechnology industries to redefine translational research and establish ground-breaking therapeutics via our drug discovery solutions.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Strengthens Pre-Clinical Leadership Team with Senior Appointment
The company has appointed Laurie Heilmann as senior vice president.
Friday, July 03, 2015
Crown Bioscience Expands its Partnership with The National Resource Center for Mutant Mice
The expanded collaboration will focus on developing immuno-oncology mouse models and other disease-specific experimental models supporting translational medical research.
Friday, July 03, 2015
Crown Bioscience Acquires Molecular Response’s PDX Business
Company is acquiring all of Molecular Response’s existing PDX models.
Friday, February 13, 2015
Crown Bioscience Expands Operations and Re-Brands UK Site
Existing facility will become centre of excellence for hormonal oncology and step up European operations.
Friday, January 09, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Bioscience President Honored in PharmaVOICE 100
Dr Jean-Pierre Wery is recognized for pioneering work in translational medicine, improving the efficiency of drug discovery and development.
Friday, August 01, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience to Showcase Progression in Human Surrogate Trials
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.
Wednesday, May 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
Crown Bioscience Announces Research Collaboration with the NRCMM
New collaboration aims to develop disease-specific experimental models for translational medical research.
Saturday, May 10, 2014
Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Crown Bioscience Acquires PRECOS
Company strengthens oncology expertise.
Monday, August 05, 2013
CrownBio Strengthens Oncology Expertise with Acquisition of PRECOS
Company has acquired the shares of Preclinical Oncology Services Limited.
Tuesday, July 30, 2013
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!